<DOC>
	<DOCNO>NCT01868035</DOCNO>
	<brief_summary>This multicenter study long-term follow-up surviving patient expect complete complete least two year follow-up treatment Iodine I 131 Tositumomab ( BEXXAR ) study CP-97-011 , CP-98-025 , CP-99-032 , CP-99-036 . All patient assess survival disease status , include subsequent therapy Diffuse Large B-cell Non-Hodgkin 's Lymphoma ( NHL ) , long-term safety . Additionally laboratory evaluation consist thyroid stimulate hormone ( TSH ) level complete blood cell ( CBC ) count differential platelet count obtain annually . Additionally , patient remain long-term response follow Iodine I 131 Tositumomab treatment follow response progression .</brief_summary>
	<brief_title>Iodine-131 Anti-B1 Antibody Consolidation Patients With Non-Hodgkin 's Lymphoma Following First-line CHOP</brief_title>
	<detailed_description>This phase II , open-label , multicenter study Iodine-131 Anti-B1 Antibody consolidation 20 patient diffuse large B-cell non-Hodgkin 's lymphoma ( NHL ) achieve partial response ( PR ) , unconfirmed complete response ( CRu ) , complete response ( CR ) follow 6-8 cycle first-line cyclophosphamide , doxorubicin , vincristine , prednisone ( CHOP ) chemotherapy . Although majority patient enter previous Iodine-131 Anti-B1 Antibody study low-grade transformed low-grade NHL , 15 patient de novo intermediate-grade NHL treat . Patients undergo two dose phase Iodine-131 Anti-B1 Antibody . In first phase , term `` dosimetric dose , '' patient receive infusion unlabeled Anti-B1 Antibody ( 450 mg ) 60 minute follow 30-minute infusion ( include 10-minute flush ) Anti-B1 Antibody ( 35 mg ) contain 5 mCi Iodine-131 . Whole body gamma camera scan obtain Day 0 ; Day 2 , 3 , 4 ; Day 6 7 follow dosimetric dose . Using dosimetric data three image time point , patient-specific dose Iodine-131 calculate deliver desire total body dose radiotherapy . In second phase , term `` therapeutic dose , '' patient receive 60-minute infusion unlabeled Anti-B1 Antibody ( 450 mg ) follow 30-minute infusion ( include 10-minute flush ) 35 mg Anti-B1 Antibody label patient-specific dose Iodine-131 calculate deliver 75 cGy total body radiation dose . Patients platelet count 100,000-149,999 cells/mm3 receive 65 cGy patient obese dose base upon 137 % lean body mass . Patients treat saturated solution potassium iodide ( SSKI ) , Lugol 's solution , potassium iodide tablet start least 24 hour prior first infusion Iodine-131 Anti-B1 Antibody ( i.e. , dosimetric dose ) continue 14 day follow last infusion Iodine-131 Anti-B1 Antibody ( i.e. , therapeutic dose ) . The primary endpoint study determine incidence Grade IV hematologic toxicity follow Iodine-131 Anti-B1 Antibody consolidation patient diffuse large B-cell NHL achieve response ( PR , CRu , CR ) follow first-line CHOP chemotherapy . The secondary efficacy endpoint determine complete response rate , duration response , duration complete response , progression-free survival , time treatment failure . The pharmacokinetic endpoint determine total body residence time follow dosimetric dose . The secondary safety endpoint determine incidence adverse experience , hematologic toxicity ( e.g. , nadir , time nadir , time recovery ) , use supportive care , percent patient convert human anti-murine antibody ( HAMA ) positivity , survival .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<mesh_term>Cadexomer iodine</mesh_term>
	<criteria>male female subject age 18 80 year , inclusive , International Prognostic Index score ; treat 6 cycle firstline CHOP chemotherapy achieve PR , CRu , CR de novo diffuse large Bcell NHL accord REAL classification ; Ann Arbor stage III , stage IV , bulky stage II disease ( mass ≥10 cm diameter ) less average 25 % intratrabecular marrow space involve NHL bilateral bone marrow biopsy specimens &lt; 10 % involvement NHL unilateral bone marrow biopsy ; tumor tissue express CD20 antigen ≥60 % performance status Karnofsky Performance Scale anticipate survival least 3 month absolute neutrophil count ( ANC ) ≥1500 cells/mm3 platelet count ≥100,000/mm3 adequate renal function ( serum creatinine &lt; 1.5 × upper limit normal [ ULN ] ) hepatic function ( total bilirubin ≤2.0 × ULN aspartate aminotransferase &lt; 5 × ULN ) prior radiation , prior biological therapy , prior chemotherapy firstline CHOP active bilateral obstructive hydronephrosis New York Heart Association class III IV heart disease serious illness prior malignancy lymphoma ( except adequately treated skin cancer , situ cervical cancer , cancer diseasefree &gt; 5 year ) human immunodeficiency virus infection HAMA positive brain leptomeningeal metastasis time since diagnosis active infection require intravenous antiinfectives pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>radioimmunotherapy</keyword>
	<keyword>Iodine 131 Tositumomab</keyword>
</DOC>